A study of a new drug combo for large B-cell lymphoma with TP53 changes
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have large B-cell lymphoma that has come back or not responded to treatment, and has a TP53 change (a mutation or deletion).
- You must not be eligible for a stem cell transplant (for example, due to age, organ problems, or your own choice).
- You must have at least one tumor that can be measured on a scan (lymph node at least 1.5 cm or other lesion at least 1 cm).
- You must be willing to follow study procedures, including using contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
This study tests a new combination of drugs for people with large b-cell lymphoma that has come back or not responded to the first treatment. It aims to see if this combination can help control the cancer and prepare for a type of cell therapy called liso-cel.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This study tests a new combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—in people with large B-cell lymphoma that has come back or not responded to earlier treatment. The goal is to see if this combination can shrink or control the lymphoma.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This trial tests a combination of two targeted drugs, polatuzumab vedotin and glofitamab, for people with large B-cell lymphoma that came back or didn't go away after their first standard treatment. The goal is to see if this combination can help control the lymphoma.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.